Life-threatening hypophosphatemia and/or phosphate depletion in a patient with acute lymphoblastic leukemia: a rare case report

Published:April 17, 2014DOI:
      Acute severe hypophosphatemia can be life threatening and is associated with mortality and impaired cardiac and respiratory function. Several conditions including decreased absorption or increased urinary phosphate excretion, shifts from the extracellular to intracellular compartments, and phosphate consumption by rapidly proliferating cells are known to induce moderate to severe acute hypophosphatemia. Although hypophosphatemia and/or phosphate depletion in patients with acute or chronic myeloid leukemia have been reported in the literature, hypophosphatemia due to acute lymphoblastic leukemia (ALL) is very rare. We report a case of history of ALL complicated by life-threatening hypophosphatemia manifesting as generalized muscle weakness, fatigue, acute shortness of breath, and difficulty in standing up and walking for 3 days. Serum inorganic phosphate levels were consistently low (0.06 mmol/L). The patient was hospitalized and thought to have a relapsed ALL. Anticancer agents and oral phosphate (660 mg twice daily) were administered. On the second day of treatment, the patient began to improve, and the patient gradually fully recovered within 5 days. We suggested that this hypophosphatemia was induced by a shift of phosphorus into leukemic cells that rapidly replicated in the tissues and excessive cellular phosphate consumption by rapidly proliferating cells. Serum phosphate levels should always be monitored, especially in suspected life-threatening manifestation in relapsed ALL.
      To read this article in full you will need to make a payment
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Emergency Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Subramaniam P.
        • Babu K.L.
        • Nagarathna J.
        Oral manifestations in acute lymphoblastic leukemic children under chemotherapy.
        J Clin Pediatr Dent. 2008; 32: 319-324
        • Morais E.F.
        • Lira J.A.
        • Macedo R.A.
        • Santos K.S.
        • Elias C.T.
        • Morais M.D.
        Oral manifestations resulting from chemotherapy in children with acute lymphoblastic leukemia.
        Braz J Otorhinolaryngol. 2014; 80: 78-85
        • Yeoh A.E1.
        • Tan D.
        • Li C.K.
        • Hori H.
        • Tse E.
        • Pui C.H.
        Management of adult and paediatric acute lymphoblastic leukaemia in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013.
        Lancet Oncol. 2013; 14: 508-523
        • Assad F.
        An evidence-based problem-solving approach to clinical cases.
        Iran J Kidney Dis. 2010; 4: 195-201
        • Amanzadeh J.
        • Reilly Jr., R.F.
        Hypophosphatemia: an evidence-based approach to its clinical consequences and management.
        Nat Clin Pract Nephrol. 2006; 2: 136-148
        • O’Regan S.
        • Carson S.
        • Chesney R.W.
        • Drummond K.N.
        Electrolyte and acid-base disturbances in the management of leukemia.
        Blood. 1977; 49: 345-353
        • Milionis H.
        • Pritsivelis N.
        • Elisaf M.
        Marked hypophosphatemia in a patient with acute leukemia.
        Nephron. 1999; 83: 173
        • Salomon O.
        • Holtzman E.J.
        • Beckerman P.
        • Avivi C.
        • Trakhtenbrot L.
        • Kneller A.
        • et al.
        Hyperphosphatemia during spontaneous tumor lysis syndrome culminate in severe hypophosphatemia at the time of blast crisis of Phneg CML to acute myelomonocytic leukemia.
        Exp Hematol Oncol. 2012; 1: 24-28
        • Zamkoff K.W.
        • Kirshner J.J.
        Marked hypophosphatemia associated with acute myelomonocytic leukemia. Indirect evidence of phosphorus uptake by leukemic cells.
        Arch Intern Med. 1980; 140: 1523-1524
        • Liamis G.
        • Elisaf M.
        Hypokalemia, hypophosphatemia and hypouricemia due to proximal renal tubular dysfunction in acute myeloid leukemia.
        Eur J Haematol. 2000; 64: 277-278
        • Mir M.A.
        • Delamore I.W.
        Hypouricaemia and proximal renal tubular dysfunction in acute myeloid leukaemia.
        Br Med J. 1974; 3: 775-777
        • Ra'anani P.
        • Lahav M.
        • Prokocimer M.
        • Poles L.
        • Theodor E.
        Life threatening hypophosphataemia in a patient with Philadelphia chromosome-positive chronic myelogenous leukaemia in acute blastic crisis.
        Postgrad Med J. 1992; 68: 283-286
        • Osorio S.
        • Noblejas A.G.
        • Durán A.
        • Steegmann J.L.
        Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response.
        Am J Hematol. 2007; 82: 394-395
        • Benítez H.
        • Arreguín L.
        • Velásquez L.
        • Bernaldez R.
        • Juan L.
        • Farfán J.
        • et al.
        Electrolytic changes in children with acute lymphoblastic leukemia during remission induction.
        Sangre (Barc). 1995; 40: 213-217
        • Muramatsu T.
        • Nakamura Y.
        • Shibuya A.
        • Suzuki H.
        • Ando M.
        Recurrence of severe hypophosphatemia associated with tumor neogenesis in a patient with acute lymphocytic leukemia who experienced acute renal failure due to tumor lysis syndrome.
        Nihon Jinzo Gakkai Shi. 2008; 50: 602-605
        • Le Prise P.Y.
        • Oudry B.
        • Richier J.L.
        Phosphate metabolism disorder in a case of acute lymphoblastic leukemia. Initial hypophosphoremia.
        Nouv Presse Med. 1974; 3: 896
        • Liamis G.
        • Milionis H.J.
        • Elisaf M.
        Medication-induced hypophosphatemia: a review.
        QJM. 2010; 103: 449-459
        • Riedler G.F.
        • Scheitlin W.A.
        Hypophosphatemia in septicemia: higher incidence in gram negative than in gram positive infections.
        Br Med J. 1969; 1: 753-756
        • Ritz E.
        Acute hypophosphatemia.
        Kidney Int. 1982; 22: 84-94
        • Supramanian R.
        • Khardori R.
        Severe hypophosphatemia. Pathophysiologic implications, clinical presentations, and treatment.
        Medicine (Baltimore). 2000; 79: 1-8
        • Mir M.A.
        • Delamore I.W.
        Metabolic disorders in acute myeloid leukemia.
        Br J Hematol. 1978; 40: 79-92
        • Betro M.G.
        • Pain R.W.
        Hypophosphataemia and hyperphosphataemia in a hospital population.
        BMJ. 1972; 1: 273-276
        • Berman E.
        • Nicolaides M.
        • Maki R.G.
        • Fleisher M.
        • Chanel S.
        • Scheu K.
        • et al.
        Altered bone and mineral metabolism in patients receiving imatinib mesylate.
        N Engl J Med. 2006; 354: 2006-2013
        • Coyle S.
        • Masters P.W.
        • Barnard D.
        TmP/GFR and ionized calcium in the management of severe hypophosphataemia.
        Ann Clin Biochem. 1992; 29: 567-569
        • Lentz R.D.
        • Brown D.M.
        • Kjellstrand C.M.
        Treatment of severe hypophosphatemia.
        Ann Intern Med. 1978; 89: 941-944